Navigation Links
BMP Sunstone Completes Acquisition of Shanghai Rongheng Pharmaceutical Co., Ltd
Date:7/7/2008

PLYMOUTH MEETING, Pa., July 7 /Xinhua-PRNewswire/ -- BMP Sunstone Corporation (Nasdaq: BJGP; ''BMP Sunstone'' or the ''Company'') today announced that it received the New Business License for BMP Sunstone's establishment of an enterprise with foreign investment in the People's Republic of China, from the Shanghai Administration for Industry and Commerce (SHAIC). With receipt of this license, the Company has completed the acquisition of 63.3 percent of Shanghai Rongheng Pharmaceutical Co., Ltd. (''Rongheng''). Shanghai Rongheng International Trade Co., Ltd. of Orient International (Holding) Co., CAS Shanghai Shenglongda Biotech Group and one other individual own the remainder of Rongheng.

David Gao, Chief Executive Officer of BMP Sunstone stated, "We are very pleased to complete the Rongheng acquisition, which is one more important step in our corporate mission to control direct access to the high end pharmaceutical markets in Beijing, Shanghai and the Guangdong province. These areas are China's top pharmaceutical markets and generate roughly 60 percent of all high-end pharmaceutical imports into the country. Through this acquisition, BMP Sunstone will gain direct coverage of 80 percent of the top-tier hospitals and 40 percent of the retail pharmacies in Shanghai, which enable us to penetrate the market more effectively and increase our market share in this important city.''

Rongheng is a pharmaceutical distribution company which distributes over 400 pharmaceutical products to more than 140 top-tier hospitals and 1,000 retail pharmacies in Shanghai. Rongheng was founded in 1999 by CAS Shanghai Shenglongda Biotech Group, a high-tech biomedical group focused on research and development, marketing and sales of new biotechnology and pharmaceuticals in China, and Orient International (Holding) Co., one of the largest foreign trade enterprises in China.

Mr. Gao continued, ''We believe that today's achievement is in the best interest of our customers, employees and shareholders and I'd like to thank all of our constituents for their hard work completing this acquisition. The closing of the Rongheng acquisition marks a major milestone for BMP Sunstone to complete our strategic initiatives to establish distribution networks in China.''

About BMP Sunstone Corporation

BMP Sunstone Corporation is a specialty pharmaceutical company that is building a proprietary portfolio of branded pharmaceutical and healthcare products in China and is pursuing partnerships with other companies seeking to enter the Chinese pharmaceutical market. It is the only U.S. public company to offer industry partners a comprehensive suite of market-entry services in China that includes pre-market entry analysis, clinical trial management, product registration, market research, as well as pharmaceutical marketing and distribution. The Company provides distribution services for a wide range of products, including Western medicines, traditional Chinese medicines, bio-chemical medicines, medical applications, branded generic pharmaceuticals, over-the-counter healthcare products, and home healthcare supplies and equipments. BMP Sunstone's proprietary portfolio primarily focuses on women's health and pediatrics. The Company is headquartered in Plymouth Meeting, Pennsylvania.

For more information, please contact:

BMP Sunstone Corporation

Fred M. Powell

Chief Financial Officer

Tel: +1-610-940-1675

Integrated Corporate Relations, Inc.

Ashley Ammon MacFarlane and Christine Duan

Tel: +1-203-682-8200 (Investor Relations)


'/>"/>
SOURCE BMP Sunstone Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. BMP Sunstone Announces Official Launch of Ferriprox in PRC
2. BMP Sunstone Announces Participation in June Investor Conferences
3. BMP Sunstone Reports First Quarter 2008 Financial Results
4. BMP Sunstone Donates RMB 1.2 Million to Earthquake Relief
5. BMP Sunstone Announces Participation in May Investor Conferences
6. BMP Sunstone to Report First Quarter 2008 Financial Results
7. BMP Sunstones Propess(R) Recommended as First Line Treatment By the Chinese Medical Association
8. USHIFU, LLC Completes Acquisition of Focus Surgery, Inc.
9. Southern Home Medical Equipment Completes 1-for-1,000 Reverse Split and Begins Trading Under New Symbol SHOM
10. KV Pharmaceutical Company Completes Fiscal 2008 Filings With Securities and Exchange Commission
11. Beeston completes drilling on Bluff Lake property, 100 Mile House
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... 2017 , ... The Center for Autism and Related Disorders ... Research and Treatment (RI-CART) and Cinemaworld to present Sensory Friendly Films. The events ... films in an environment that accommodates their unique needs. , Launched in January, ...
(Date:2/23/2017)... ... 2017 , ... Curemark, LLC announced today that the Blüm Study, a Phase ... 3-8 with Autism, is now enrolling at three new sites. These new sites are ... , “There are currently no approved drugs that address the core symptoms of ...
(Date:2/22/2017)... ... February 22, 2017 , ... When it came ... contact center in Georgia, PENETRON Specialty Products (PSP) provided the solution. January’s grand ... recently invested $51 million to purchase and renovate the 185,000 square-foot office complex, ...
(Date:2/22/2017)... , ... February 22, 2017 , ... The Waismann ... the thousands of individuals who have recently fallen victim to America’s opioid epidemic. Now, ... Orange County, California, where they are free from the shame, stigma, and harmful ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... to fewer trips the emergency room, fewer hospital admissions, and better blood pressure ... Managed Care® (AJMC®) finds. The study can be found here . , ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... DUBLIN , Feb 23, 2017 Research ... Prosthetic Devices Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 9.2% over the next ... industry report analyzes the market estimates and forecasts for all the ...
(Date:2/23/2017)... 23, 2017 MabVax Therapeutics Holdings, ... development company, announces that it has received notice ... authorizing the initiation a Phase I clinical trial ... cancer. MVT-1075 ( 177 Lu-CHX-A?-DTPA-HuMab5B1) is the Company,s ... to initiate the phase I clinical trial in ...
(Date:2/23/2017)... , Feb. 22, 2017 Orthopedic ... implant demand, as aging demographic patterns lead to ... Implants for sports- and exercise-related injuries, chronic back ... will lead sales gains. The future of medical ... addresses the following questions and more: - ...
Breaking Medicine Technology: